Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.45 |
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19637617 | 1.00 | KRAS (0.45) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19948569 | 1.00 | KRAS (0.45) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19959367 | 0.95 | KRAS (0.45) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL30188633 | 0.95 | KRAS (0.45) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL29246035 | 0.95 | KRAS (0.45) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19964238 | 0.91 | KRAS (0.44) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19616467 | 0.91 | KRAS (0.56) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19617279 | 0.91 | KRAS (0.56) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL30188819 | 0.91 | KRAS (0.56) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19616721 | 0.91 | KRAS (0.56) | KRASVHLCDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |